SimpleScreen CRC Updated Nov 14
SimpleScreen CRC's defining binary (FDA approval) has passed, removing the high-impact binary catalyst. The stock now trades on the commercial execution story via Abbott and on pipeline expansion (lung test). Watch Q4 2026 revenue (due early 2027) for evidence of recurring test-sale volume versus one-time milestones; the next-gen validation data and a potential FDA filing for the updated version are the next potential catalysts to watch for.
- FDA-approved and commercially launched: the test is the second blood-based CRC screening test to reach the US market, and Abbott handles all US commercialization, giving Freenome a powerful distribution partner.
- Q32026 results show the business model working: revenue jumped to $183.5 million (from $1 million) and EPS of $0.57 beat the $0.41 consensus, driven by milestone revenue from Abbott.
- Analyst consensus is overwhelmingly bullish: 6 Strong Buy, 4 Buy, and only 1 Hold, with a mean price target of $18 (72.9% implied upside from $10.41).
- Competition is intensifying: Guardant Health's Shield blood test (approved 2024) has first-mover advantage and expanding insurance coverage. Abbott's ownership of both Cologuard Plus (stool) and SimpleScreen CRC (blood) may cannibalize one or the other.
- Clinical performance is mid-tier: SimpleScreen CRC's ~81% sensitivity for colorectal cancer lags behind stool-based tests like Cologuard (over 90%) and colonoscopy (the gold standard). The test is positioned as a second-line option for those unwilling to do stool tests or colonoscopy, not as a replacement.
- Stock dropped 11% in October 2026 after the next-gen data at ACG showed 'clinically meaningful' improvement but apparently disappointed expectations for bigger gains.